NYSE:NYT
NYSE:NYTMedia

New York Times (NYT) Margin Beat Reinforces Quality Earnings Narrative Despite Slower Growth Outlook

The New York Times (NYT) reported a net profit margin of 12%, edging above last year's 10.9%, with earnings growing at an 18.9% annual pace over the past five years. Looking ahead, earnings are forecast to climb at 12.55% per year, but both this and revenue growth projections of 5.6% annually trail the wider US market’s estimates. With a strong historical track record and shares trading below an estimated fair value, investors may see the rising margins and solid earnings quality as...
NasdaqGM:OABI
NasdaqGM:OABILife Sciences

OmniAb (OABI): Losses Widen 30.8% Annually, Challenging Bulls Despite 30.4% Revenue Growth Forecast

OmniAb (OABI) remains in the red, with losses climbing at an average rate of 30.8% annually over the past five years and no improvement in net profit margin. The company is expected to stay unprofitable for at least the next three years, ruling out traditional earnings growth comparisons. However, investors are eyeing a forecasted 30.4% annual revenue increase, which is well ahead of the US market's 10.5% average. With persistent unprofitability and high valuation multiples balanced against...
NYSE:RDN
NYSE:RDNDiversified Financial

Radian Group (RDN) Value Discount Persists as Margin Compression Challenges Bullish Narratives

Radian Group (RDN) posted annual earnings growth of 5.1% over the past five years, but its earnings slipped over the last year and are projected to rise only 3.7% annually going forward. Revenue is on track to grow at 6.5% each year, trailing the US market average of 10.5%. The recent net profit margin came in at 45.6%, down from 47.1% last year. Investors may see the lower price-to-earnings ratio of 7.9x as a value opportunity versus its peers. However, growth prospects appear more modest...
NYSE:DOCN
NYSE:DOCNIT

DigitalOcean (DOCN) Net Margin Rises to 15.2%, Reinforcing Profitability Narrative

DigitalOcean Holdings (DOCN) came in with a forecast of 15.5% annual revenue growth, topping the broader US market forecast of 10.5%. The company’s earnings are expected to climb 22.2% per year, outpacing the national average of 16%, and net profit margins have increased to 15.2% from last year's 9.3%. After a standout year of 84.9% earnings growth and five-year annualized growth of 78.1%, DigitalOcean is establishing itself as a consistently profitable player. See our full analysis for...
NasdaqGS:MRCY
NasdaqGS:MRCYAerospace & Defense

Mercury Systems (MRCY): Losses Deepen as Profit Growth Forecasts Test Turnaround Narrative

Mercury Systems (MRCY) reported continued unprofitability, with losses expanding at an average rate of 73.9% per year over the last five years. Despite the lack of net income, the company’s earnings are expected to grow by 102.49% annually, and profitability is projected within the next three years. This pace of profit growth is anticipated to exceed that of the broader market. The stock is currently priced at $78.13, which sits above its estimated fair value of $59.15. Its Price-to-Sales...
NasdaqGS:MTCH
NasdaqGS:MTCHInteractive Media and Services

Match Group (MTCH): Profit Margins Slip, Undermining Bullish Narratives Despite Strong Valuation

Match Group (MTCH) has seen earnings rise 7% per year over the last five years, and profits are forecast to grow at 11.7% per year going forward. Net profit margins in the latest period landed at 15.6%, down from 18.7% a year earlier. Revenue growth is expected to trail the broader market, with forecasts for a 5.4% annual pace compared to the US market’s 10.5%. See our full analysis for Match Group. Next up, we will see how these headline numbers play out against the current narratives and...
NYSE:VSH
NYSE:VSHElectronic

Vishay Intertechnology (VSH): Losses Worsen 16.6% Annually, Profitability Concerns Challenge Bullish Narratives

Vishay Intertechnology (VSH) has remained unprofitable, with net losses worsening at a rate of 16.6% per year over the past five years. The company’s net profit margin has shown no improvement, and investors have been unable to assess any quality or positive acceleration in underlying earnings. At the same time, Vishay’s Price-To-Sales ratio sits at 0.7x, notably lower than both the US Electronic industry average of 2.6x and the peer average of 2.4x. However, its share price of $15.32...
NasdaqGS:NFLX
NasdaqGS:NFLXEntertainment

Has the Recent 24% Rally Made Netflix Too Expensive for Investors in 2025?

Ever wondered if Netflix is actually worth its sky-high share price, or if the recent buzz outweighs its real value? You are definitely not alone in asking that question right now. Netflix has seen some dramatic moves, with a 23.9% gain year-to-date and a staggering 331.3% return over the past three years, despite a slight 5.6% dip in the last month. Investor optimism has been fueled by headlines about Netflix's continuing expansion into global markets and its strategic push into gaming and...
OTCPK:CBCY
OTCPK:CBCYBanks

Assessing Central Bancompany (CBCY) Valuation After Strong Earnings and Rising Investor Optimism

Central Bancompany (CBCY) has just released its latest earnings, reporting stronger net interest income and net income for the nine months ending September 30, 2025, compared to the same period last year. Investors are taking note of this growth. See our latest analysis for Central Bancompany. Central Bancompany’s upbeat financials appear to be fueling fresh momentum in its share price. The stock climbed 8% over the past 30 days and has delivered a robust 59% share price return so far this...
NYSE:LPX
NYSE:LPXForestry

Louisiana-Pacific (LPX) Profit Margin Decline Tests Bullish Growth Narratives Ahead of Earnings Season

Louisiana-Pacific (LPX) posted a net profit margin of 10.3%, down notably from the prior year's 15.2%, marking a narrower spread for the period. Despite earnings having declined at an average annual rate of 24.2% over the past five years, forecasts now point to a significant turnaround. Expected earnings growth of 29.3% per year is anticipated to outpace the broader U.S. market’s 16% projected pace. Investors are likely to weigh this mix of margin compression and upbeat growth outlook as the...
NYSE:CPNG
NYSE:CPNGMultiline Retail

Coupang (CPNG) Surpasses Q3 Earnings Estimates Will Automation Drive Sustainable Profit Growth?

Coupang reported third-quarter 2025 earnings, with revenue rising to US$9.27 billion and net income reaching US$95 million, both above the prior year's figures. Management pointed to continued gains in Coupang Eats and Coupang Play, underlining ecosystem growth and the positive impact of investments in automation and logistics. We'll examine how Coupang's strong revenue growth and improved profitability shape the investment narrative for its core and expanding segments. Uncover the next big...
NasdaqGM:CDNA
NasdaqGM:CDNABiotechs

CareDx (CDNA): Profit Driven by $89.4 Million One-Off Gain Raises Earnings Sustainability Questions

CareDx (CDNA) shifted into profitability this quarter, backed by forecasts that call for robust annual earnings growth of about 80.2% and revenue growth of 11.1% per year for the next three years. The company’s $16.53 share price and Price-To-Earnings Ratio of 15.1x compare favorably to industry and peer averages. However, the recent results were buoyed by a significant, non-recurring gain of $89.4 million. With these headline numbers and a valuation still above the estimated fair value of...
NYSE:WWW
NYSE:WWWLuxury

Wolverine World Wide (WWW) Profitability Return Reinforces Bull Narratives as Forecasts Top Market Growth

Wolverine World Wide (WWW) has recently turned a profit, with its net profit margin improving over the past year. Earnings are forecast to grow an impressive 27.7% per year, outpacing the broader US market's 16% projection. The five-year annual earnings growth sits at 4.6%. With revenue expected to rise 7.1% per year going forward and the shares trading at $16.72, the company delivers high-quality earnings and maintains value metrics that stand out compared to peers. However, its financial...
NasdaqGM:EYPT
NasdaqGM:EYPTPharmaceuticals

EyePoint Pharmaceuticals (EYPT): Persistent Losses Challenge Bullish Revenue Growth Narrative

EyePoint Pharmaceuticals (EYPT) remains unprofitable, with losses increasing at an annual rate of 25.2% over the past five years. While the company is forecast to stay in the red for at least three more years, revenue is projected to surge by 61.3% per year, outpacing the broader US market's expected 10.5% annual growth. Investors are weighing these robust revenue forecasts against ongoing share dilution and persistent unprofitability as they consider EyePoint’s current valuation. See our...
NasdaqGS:WEYS
NasdaqGS:WEYSRetail Distributors

Weyco Group (WEYS) Margin Miss Challenges Value-Focused Bull Narratives

Weyco Group (WEYS) reported a net profit margin of 9.2% for the period, down from 10% last year, reflecting recent pressure on profitability. Despite this, the company stands out for its historically high earnings quality, with five-year annual earnings growth averaging a robust 31.5%. Its shares trade at $31.35, well below an estimated fair value of $90.59. Value-focused investors are likely to take note of its discounted price-to-earnings multiple and appealing dividend, although the latest...
NYSE:JLL
NYSE:JLLReal Estate

JLL: Profit Margin Up to 2.3% Challenges Cautious Narratives on Recovery and Valuation

Jones Lang LaSalle (JLL) posted annual revenue growth of 7.2%, trailing the broader US market’s 10.5% pace, while EPS is forecast to grow 15.3% per year, just under the US average of 16%. Over the past year, profit margins moved up from 1.8% to 2.3% and the company swung to positive earnings growth, up 47.4% after several years of decline. With high-quality earnings and valuation metrics below both peer and industry averages, these results could give investors reasons to view JLL’s latest...
NYSE:U
NYSE:USoftware

Unity (U) Losses Accelerate 10.8% Annually, Extending Profit Worries Versus Growth Narratives

Unity Software (U) remains in the red, with losses deepening by 10.8% per year over the past five years and no notable shift in profitability metrics. Revenue is forecast to grow at 10% annually, slightly lagging the broader US market's 10.5%. With shares trading at $42.36, well above the estimated fair value of $36.45 and a price-to-sales ratio of 10.1x that surpasses both peer and industry averages, investors see a company priced for growth but still searching for sustained profits in the...
NYSE:AGL
NYSE:AGLHealthcare

agilon health (AGL): Losses Persist, Challenging Bull Case Despite Forecast 10.7% Revenue Growth

agilon health (AGL) is expected to post revenue growth of 10.7% per year, slightly outpacing the broader US market’s 10.5% rate. The stock trades at $0.75 per share, which is significantly below its estimated fair value of $13.21 and reflects a substantial discount on key valuation metrics such as its 0.1x Price-to-Sales ratio. Despite this growth outlook, the company remains unprofitable and losses have been increasing by 7.9% annually over the past five years, which continues to put...
NYSE:NVGS
NYSE:NVGSOil and Gas

Navigator Holdings (NVGS) Margin Expansion Challenges Slow Growth Narrative After Earnings Release

Navigator Holdings (NVGS) posted a net profit margin of 15.6%, edging up from 14.8% a year earlier, with earnings growth of 6.7% over the past year following a robust five-year average annual growth of 55.1%. While the company’s price-to-earnings ratio of 12.6x underscores its value orientation compared to US oil and gas peers, shares recently traded at $16.93 and sit above the internally estimated fair value of $2.68. Looking ahead, investors are weighing improved profitability and...
NasdaqGS:CHRD
NasdaqGS:CHRDOil and Gas

Chord Energy (CHRD) One-Off $578M Loss Sparks Margin Quality Debate

Chord Energy (CHRD) posted net profit margins of 5.3% for the twelve months leading up to September 30, 2025, down sharply from 22.2% a year earlier. This decline was largely driven by a one-off $578 million loss that weighed on earnings results for the period. Looking ahead, investors are weighing the short-term margin pressure and non-recurring losses against robust forward-looking projections. Annual earnings growth of 37.2% is expected and could outpace the broader US market. See our full...
NYSE:MBI
NYSE:MBIInsurance

MBIA (MBI) Losses Narrow 3.2% Annually, Valuation Still High Versus Insurance Peers

MBIA (MBI) continues to operate at a loss, but over the last five years the company has narrowed those losses at an average annual rate of 3.2%. Despite this gradual progress, MBIA’s net profit margin is still in negative territory, and its valuation stands out. The Price-to-Sales Ratio sits at 3.5x, which is significantly higher than both the US insurance industry average of 1.1x and a peer group average of 1.3x. With profitability still out of reach and no fair value estimate available,...
NasdaqGS:UPST
NasdaqGS:UPSTConsumer Finance

Upstart (UPST) Margin Turnaround Timeline Reinforces Bull Narratives Despite Premium Valuation Concerns

Upstart Holdings (UPST) is forecast to grow earnings by 56.05% per year and increase revenue at an annual rate of 18.8%, outpacing the broader US market’s 10.5% growth projection. Despite the strong outlook, the company remains unprofitable, with losses having accelerated at 43.8% annually over the past five years. Investors will note the current Price-to-Sales ratio of 4.6x sits above industry and peer averages. With shares trading at $41.75, below analysts’ fair value estimate of $47.40,...
NasdaqGS:CBLL
NasdaqGS:CBLLMedical Equipment

CeriBell (CBLL) Revenue Growth Outpaces Market, But Persistent Losses Test Bullish Narrative

CeriBell (CBLL) is forecast to grow revenue by 23.39% per year, outpacing the US market’s projected 10.5% annual increase. Despite this trajectory, the company remains unprofitable and is not expected to reach profitability within the next three years, with no evidence of net profit margin improvement over the last twelve months. Investors are likely to weigh CeriBell's robust top-line expansion against continued losses and a valuation multiple well above peers. See our full analysis for...
NasdaqGS:STOK
NasdaqGS:STOKBiotechs

Stoke Therapeutics (STOK) Profitability Milestone Tests Bullish Narratives as Earnings Face Declines

Stoke Therapeutics (STOK) has moved into profitability over the past year and is now forecasting revenue growth of 20.1% per year, which handily outpaces the broader US market's 10.5% annual growth expectation. However, earnings are projected to decline by 5.6% each year over the next three years, suggesting the company's recently achieved profit status may be tested as the bottom line comes under pressure. The premium valuation and mixed outlook put investor attention squarely on how...